Pay in 4 interest-free payments of $7.14 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
Trulicity (dulaglutide) EMA Product Information (PDF)
Olateju IV et al
MEDVi states the program starts at $179 for the first month with no contract, covering the physician review, plan, coaching and the medication itself, and that refills are then locked in at $299/mo
The most important development for these two compounds specifically is that both were rejected by the FDA's Pharmacy Compounding Advisory Committee (PCAC) in late 2024
About ACHIEVE-1 and ACHIEVE clinical trial program ACHIEVE-1 (NCT05971940) is a Phase 3, 40-week, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of orforglipron 3 mg, 12 mg and 36 mg as monotherapy to placebo in adults with type 2 diabetes and inadequate glycemic control with diet and exercise alone
US$ 22.33
US$ 24.06
US$ 26.13
US$ 20.69
US$ 26.63
